|
KMID : 0882420180930020172
|
|
Korean Journal of Medicine
2018 Volume.93 No. 2 p.172 ~ p.180
|
|
|
Biologic Treatment of Severe Asthma
|
|
Kim Min-Hye
|
|
|
Abstract
|
|
|
|
Beyond the existing scope of asthma treatment, a number of biologics have recently been developed based on the immunopathological mechanism of severe asthma. Severe asthma has a wide variety of phenotypes or endotypes, more than half of which are associated with eosinophils or type 2 inflammation. This paper introduces newly developed biologics and those that are under development for treatment of asthma. The most successful biologics developed to date are anti-IgE and anti-interleukin (IL)-5 antibodies, followed by anti-IL-4, anti-IL-13, anti-prostaglandin D2 type 2 receptor, and anti-thymic stromal lymphopoietin antibodies. However, further studies on drugs that target type 1 inflammation are required.
|
|
|
KEYWORD
|
|
|
Asthma, Status asthmaticus, Biological therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|